Inegy (Simvastatin, Ezetimibe)

Simvastatin blocks HMG‑CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, reducing internal cholesterol production. Ezetimibe inhibits the NPC1L1 transporter in the intestine, preventing absorption of dietary and biliary cholesterol. The dual action decreases both endogenous and exogenous cholesterol, leading to lower blood cholesterol concentrations.

The specific dose of Inegy is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerance. Dosage may be adjusted after laboratory monitoring, and the prescriber will provide individualized instructions that align with current clinical guidelines.

Safety of Inegy in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To order Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details, and any necessary import documentation.

Inegy offers a fixed‑dose combination of a statin (simvastatin) and a cholesterol absorption inhibitor (ezetimibe), which can provide greater LDL‑cholesterol reduction than a statin alone. Compared with separate tablets, the combination may improve adherence and simplify dosing, while delivering comparable efficacy to other high‑intensity statin‑plus‑ezetimibe regimens.

Inegy tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources, and discard any tablets that appear discolored or damaged.

Inegy is taken orally, usually once daily in the evening, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and may be taken with or without food, unless the prescriber provides specific instructions regarding meals.

The most serious adverse events associated with Inegy include rhabdomyolysis (muscle breakdown that can lead to kidney failure), severe liver injury, and life‑threatening allergic reactions such as anaphylaxis. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or signs of a severe allergic response to their healthcare provider.

Inegy should be avoided in individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, or a known hypersensitivity to simvastatin, ezetimibe, or any excipients. It is also contraindicated in patients taking strong CYP3A4 inhibitors or gemfibrozil, as these combinations markedly increase the risk of muscle toxicity.